Why BeOne Medicines AG (ONC) Stock Rose 6.4% on Oct 15, 2026
What happened
BeOne Medicines gained 5.73% to $371.62 after receiving a Zacks Rank #1 (Strong Buy) designation on October 15, 2026, accompanied by upward earnings revisions and analyst price-target increases from RBC Capital ($459), JPMorgan ($445), and Truist ($420), per Zacks. The Zacks Consensus Estimate for full-year earnings rose 15.2% over the prior 60 days. Volume of 302,713 shares ran 1.73x the intraday average, suggesting normal institutional participation.
BeOne Medicines earnings scheduled for November 5, 2026; consensus EPS estimate $1.89.
Other developments that session
Zacks added ONC to its Rank #1 Strong Buy list on October 15, 2026.
Frequently asked questions
Why did BeOne Medicines AG (ONC) stock rise on Oct 15, 2026?
BeOne Medicines gained 5.73% to $371.62 after receiving a Zacks Rank #1 (Strong Buy) designation on October 15, 2026, accompanied by upward earnings revisions and analyst price-target increases from RBC Capital ($459), JPMorgan ($445), and Truist ($420), per Zacks. The Zacks Consensus Estimate for full-year earnings rose 15.2% over the prior 60 days. Volume of 302,713 shares ran 1.73x the intraday average, suggesting normal institutional participation.
How much did ONC stock rise on Oct 15, 2026?
ONC rose 6.4% during the Oct 15, 2026 trading session.